DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder
-
Germany's far-right AfD holds march after Christmas market attack
-
European, US markets wobble awaiting Santa rally
-
Serie A basement club Monza fire coach Nesta
-
Mozambique top court confirms ruling party disputed win
-
Biden commutes almost all federal death sentences
-
Syrian medics say were coerced into false chemical attack testimony
-
NASA solar probe to make its closest ever pass of Sun
-
France's new government to be announced Monday evening: Elysee
-
London toy 'shop' window where nothing is for sale
-
Volkswagen boss hails cost-cutting deal but shares fall
-
Accused killer of US insurance CEO pleads not guilty to 'terrorist' murder
-
Global stock markets mostly higher
-
Not for sale. Greenland shrugs off Trump's new push
-
Sweden says China blocked prosecutors' probe of ship linked to cut cables
-
Acid complicates search after deadly Brazil bridge collapse
-
Norwegian Haugan dazzles in men's World Cup slalom win
-
Arsenal's Saka out for 'many weeks' with hamstring injury
-
Mali singer Traore child custody case postponed
-
France mourns Mayotte victims amid uncertainy over government
-
UK economy stagnant in third quarter in fresh setback
-
Sweden says China denied request for prosecutors to probe ship linked to cut undersea cables
-
African players in Europe: Salah leads Golden Boot race after brace
-
Global stock markets edge higher as US inflation eases rate fears
-
German far-right AfD to march in city hit by Christmas market attack
-
Ireland centre Henshaw signs IRFU contract extension
-
Bangladesh launches $5bn graft probe into Hasina's family
-
US probes China chip industry on 'anticompetitive' concerns
-
Biden commutes sentences for 37 of 40 federal death row inmates
-
Clock ticks down on France government nomination
-
'Devastated' Australian tennis star Purcell provisionally suspended for doping
-
Mozambique on edge as judges rule on disputed election
-
Mobile cinema brings Tunisians big screen experience
-
Philippines says to acquire US Typhon missile system
-
Honda and Nissan to launch merger talks
-
Police arrest suspect who set woman on fire in New York subway
-
China vows 'cooperation' over ship linked to severed Baltic Sea cables
-
Australian tennis star Purcell provisionally suspended for doping
-
Asian markets track Wall St rally as US inflation eases rate fears
-
Luxury Western goods line Russian stores, three years into sanctions
-
Wallace and Gromit return with comic warning about AI dystopia
-
Philippine military says will acquire US Typhon missile system
-
Afghan bread, the humble centrepiece of every meal
-
Honda and Nissan expected to begin merger talks
-
'Draconian' Vietnam internet law heightens free speech fears
-
Israeli women mobilise against ultra-Orthodox military exemptions
-
Asian markets track Wall St rally as US inflation eases rate worries
-
Tens of thousands protest in Serbian capital over fatal train station accident
-
Trump vows to 'stop transgender lunacy' as a top priority
-
Daniels throws five TDs as Commanders down Eagles, Lions and Vikings win
-
'Who's next?': Misinformation and online threats after US CEO slaying
NYSE - LSE
DEA Continues to Block MMJ Marijuana Drug Development for Neurological Disorder
MMJ Submits FDA Investigational New Drug Application for Cannabis-Derived Drug
MMJ International Holdings has taken a significant step forward by submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for its novel cannabis-derived medication. This significant move anticipates FDA approval to initiate comprehensive clinical trials, focusing on the treatment of chorea associated with Huntington's disease (HD). This step is a testament to MMJ's dedication to harnessing the therapeutic benefits of cannabis in advancing medical science.
In addition to this application, MMJ has secured an Orphan Drug designation, which highlights its commitment to addressing the critical needs of Huntington's disease patients. This designation facilitates a faster clinical trial process, focusing on validating the efficacy of their investigational drug.
Despite facing regulatory challenges, MMJ remains steadfast in its mission to develop impactful cannabinoid-derived medicines. The upcoming Phase 2 clinical trial for MMJ-002 aims to showcase its potential to significantly mitigate the debilitating effects of Huntington's chorea, with the goal of enhancing clinical outcomes and improving patient quality of life.
MMJ's commitment extends beyond U.S. borders, as it navigates through DEA-imposed barriers to marijuana drug development. The company has strategically expanded its drug development operations internationally, circumventing domestic regulatory hurdles. This international approach is due to ongoing legal disputes involving the Department of Justice (DOJ) and the DEA, which are accused of contravening the presidential marijuana research act.
With a robust approach to drug discovery and development, supported by a strong intellectual property portfolio and manufacturing expertise, MMJ International Holdings continues to spearhead innovations in the medical cannabis landscape, pushing the boundaries of what is possible in cannabinoid medicine.
MMJ is represented by Attorney Megan Sheehan of Rhode Island.
CONTACT:
Madison Hisey
mhisey@mmjih.com
203-231-8583
SOURCE: MMJ International Holdings
D.Sawyer--AMWN